Innate Pharma S.A. (IPHA)
| Market Cap | 93.07M -44.4% |
| Revenue (ttm) | 11.21M -22.4% |
| Net Income | -54.22M |
| EPS | -0.56 |
| Shares Out | 93.70M |
| PE Ratio | n/a |
| Forward PE | 20.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 64,652 |
| Open | 0.9120 |
| Previous Close | 1.0300 |
| Day's Range | 0.9120 - 0.9838 |
| 52-Week Range | 0.9300 - 2.7100 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 8.00 (+751.15%) |
| Earnings Date | Sep 17, 2026 |
About IPHA
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking ant... [Read more]
Financial Performance
In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for IPHA stock is "Buy." The 12-month stock price target is $8.0, which is an increase of 751.15% from the latest price.
News
Leerink downgrades Innate Pharma to Market Perform, lowers target to $1
As previously reported, Leerink downgraded Innate Pharma (IPHA) to Market Perform from Outperform with a price target of $1, down from $5. The firm cites the long development path ahead…
Innate Pharma downgraded to Market Perform from Outperform at Leerink
Leerink downgraded Innate Pharma (IPHA) to Market Perform from Outperform with a $1 price target
Innate Pharma Transcript: Study update
IPH4502 showed manageable phase I safety and preliminary antitumor activity, including in post-EV urothelial cancer. Planned dose optimization will test split dosing with mandatory stomatitis prophylaxis.
Innate Pharma Press release: Study update
Innate Pharma issued a press release on November 18, 2026, disclosing material business information to investors.
Innate Pharma Slides: Study update
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on November 18, 2026.
Innate Pharma S.A. Presents Initial Phase 1 Clinical Data for IPH4502
Innate Pharma S.A. announced initial Phase 1 clinical data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate incorporating an exatecan payload, in patien...
Innate Pharma presents initial IPH4502 study data
Innate Pharma (IPHA) announced initial Phase 1 data from its ongoing study of IPH4502, an investigational Nectin-4-targeting antibody-drug conjugate, or ADC, incorporating an exatecan payload, in pati...
Innate Pharma Presents Initial Phase 1 Clinical Data for IPH4502 at ENA 2026
MARSEILLE, France--(BUSINESS WIRE)-- #ADC--Innate Pharma presents initial Phase 1 clinical data for IPH4502 at ENA 2026.
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on November 18, 2026.
Innate Pharma S.A. to Host Event on IPH4502 on November 18, 2026
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host an event focused on IPH4502, its proprietary Nectin-4 ADC. The event will be held in ...
Innate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to host in-person and virtual event on IPH4502 on November 18, 2026.
Innate Pharma Transcript: Stifel 2026 Healthcare Conference 2026
IPH4502 dose-finding results are due the week of Nov. 18, 2026, while lacutamab’s TELLOMAK-3 trial is expected to start in Q1 2027. Accelerated approval is targeted for H1 2028; PACIFIC-9 results are expected in H1 2027.
Innate Pharma Q3 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the com...
Innate Pharma Earnings Call Transcript: Q3 2026
The portfolio advanced with TELLOMAK-3 initiation, an effective $75 million Sobi upfront payment, and €96.8 million in cash supporting a runway through Q1 2028. IPH4502 data are due in November 2026 and PACIFIC-9 results are expected in H1 2027.
Innate Pharma Earnings release: Q3 2026
Innate Pharma released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Innate Pharma Earnings release: Q3 2026
Innate Pharma released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
Innate Pharma Slides: Q3 2026
Innate Pharma has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
Innate Pharma Reports Third Quarter 2026 Business and Financial Update
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its financial update for the nine mon...
Innate Pharma Slides: Corporate presentation
Innate Pharma has posted slides in relation to its latest quarterly earnings report, which was published on October 28, 2026.
Innate Pharma S.A. Announces PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
Innate Pharma S.A. announced that AstraZeneca has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second half of 2026 previously...
Innate Pharma announces AstraZeneca updated timing for PACIFIC-9 data readout
Innate Pharma (IPHA) announced that AstraZeneca (AZN) has updated the expected timing for the PACIFIC-9 Phase 3 trial high-level data readout to the first half of 2027, from the second…
Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca has updated the exp...
Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference.
Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update
MARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma announces conference call for third quarter 2026 business and financial update.
Innate Pharma Q2 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said its first-half 2026 developments included the closing of a strategic partnership with Sobi for lacutamab, completion of dose-escalation enrollment for IPH4502, and comp...